Innoviva (INVA) Profit After Tax Growth (1y) (2011 - 2026)
Innoviva (INVA) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 0.26% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -107.76% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 101.22% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Innoviva | 1.58 Bn | 979.49 Mn | 75.83 Mn | 500.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 500.56% |
| Dec 31, 2025 | -4,880.69% |
| Sep 30, 2025 | 3,397.12% |
| Jun 30, 2025 | 277.49% |
| Mar 31, 2025 | -3.82% |
| Dec 31, 2024 | 113.10% |
| Sep 30, 2024 | -97.41% |
| Jun 30, 2024 | -26.56% |
| Mar 31, 2024 | -228.69% |
| Dec 31, 2023 | -92.43% |
| Sep 30, 2023 | -59.04% |
| Jun 30, 2023 | -17.95% |
| Mar 31, 2023 | -7.91% |
| Dec 31, 2022 | -70.56% |
| Sep 30, 2022 | -10.71% |
| Jun 30, 2022 | -121.68% |
| Mar 31, 2022 | -65.49% |
| Dec 31, 2021 | 8.71% |
| Sep 30, 2021 | 676.50% |
| Jun 30, 2021 | 12.85% |